Analyzing Metagenomi (MGX) & Its Rivals

Metagenomi (NASDAQ:MGX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Metagenomi to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.

Risk and Volatility

Metagenomi has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Metagenomi’s competitors have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Earnings & Valuation

This table compares Metagenomi and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metagenomi	$7.09 million	-$87.87 million	-0.30
Metagenomi Competitors	$754.80 million	$13.58 million	-18.74

Metagenomi’s competitors have higher revenue and earnings than Metagenomi. Metagenomi is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metagenomi and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1	0	2	0	2.33
Metagenomi Competitors	9869	15282	45600	1598	2.54

Metagenomi currently has a consensus price target of $6.00, indicating a potential upside of 703.21%. As a group, “Biotechnology” companies have a potential upside of 123.28%. Given Metagenomi’s higher probable upside, analysts clearly believe Metagenomi is more favorable than its competitors.

Profitability

This table compares Metagenomi and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-69.10%	-47.75%
Metagenomi Competitors	-12,323.33%	-195.38%	-30.39%

Insider & Institutional Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Metagenomi competitors beat Metagenomi on 7 of the 13 factors compared.

Metagenomi Company Profile

Metagenomi, Inc. is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools. Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction.